Search results

Skip to results

Type

Type

Last updated

Last updated

Guidance programme

Showing 1 result for olaratumab

  1. Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma (TA465)

    This guidance has been withdrawn because olaratumumab (Lartruvo) no longer has a marketing authorisation.

    Technology appraisal guidance
    Published
    9 August 2017